The “cancer immunogram”
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Visualizing the state of cancer–immune system interactions may spur personalized therapy
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“markers of response to cancer therapy have continued to evolve and now include factors well beyond established tumor-centric markers”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Blank et al., 2016
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
The metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Cited by
Items 601–700 of 748
Pesántez, D., Indacochea, A., Angelats, L., Sirico, M., Ruiz, I. V., Sanfeliu, E., Teixidó, C., González‐Navarro, E. A., Galván, P., Brasó‐Maristany, F., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00051 · Cited by 2
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
Fedele, D., Moroso, S., Turoldo, A., Bazzocchi, G., Conforti, C., Zalaudek, I., & Guglielmi, A. (2024) · Case Reports in Oncology · doi:10.1159/000535902 · Cited by 2
Lv, S., & Zhu, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95513-3.00015-0 · Cited by 4
Cai, Q., & Peng, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29126 · Cited by 2
Liu, Z., Zang, M., Li, K., Qi, W., Yuan, H., Chen, L., & Zhang, Y. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109210 · Cited by 2
Barking up the right tree: Immune checkpoint signatures of human and dog cancers
Kocikowski, M., Mayordomo, M. Y., Alfaro, J. A., & Parys, M. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013270 · Cited by 4
The Evolution of High Complexity Companion Testing for Targeted and Immuno-Oncology
Miller, I. D. (2016) · Personalized Medicine · doi:10.2217/pme-2016-0055 · Cited by 2
Adjuvant Immunotherapy as a Tool to Boost Effectiveness of Electrochemotherapy
Kamenšek, U., Valentinuzzi, K. U., & Serša, G. (2017) · Springer eBooks · doi:10.1007/978-3-319-26779-1_105-3 · Cited by 2
Immunothérapie et mélanome : l’exemple des anticorps immunomodulateurs
Pagès, C., Baroudjian, B., & Lebbé, C. (2016) · Bulletin du Cancer · doi:10.1016/s0007-4551(16)30370-8 · Cited by 2
Immun-, radio- und chemotherapeutische Studien bei Kopf-Hals-Tumoren
Schuler, P. J., Witzleben, A. V., Doescher, J., Wollenberg, B., Dietz, A., & Hoffmann, T. K. (2018) · HNO · doi:10.1007/s00106-018-0482-9 · Cited by 2
Immune Checkpoint Inhibitors in Melanoma: Review and Update
Pires, E. M., & Moura, C. (2018) · Journal of the Portuguese Society of Dermatology and Venereology · doi:10.29021/spdv.76.3.970 · Cited by 3
Development of a Nano DDS for Cancer Immunotherapy Based on Llipid Nanoparticles
Nakamura, T. (2018) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.18-00162 · Cited by 2
Personalized cancer immunotherapy
Kumar, A., Weller, K. P., & Vilgelm, A. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90949-5.00012-7 · Cited by 3
Stephen, B., & Hajjar, J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_1 · Cited by 2
Putting into Perspective the Future of Cancer Vaccines: Targeted Immunotherapy
Makhoul, I., & Kieber‐Emmons, T. (2020) · European Medical Journal · doi:10.33590/emj/19-00191 · Cited by 2
Precision Medicine in Oncology and Immuno-Oncology: Where We Stand and Where We're Headed
Scheuenpflug, J. (2017) · Biomedicine Hub · doi:10.1159/000481878 · Cited by 2
Wang, X., Xu, L., Dai, N., Yang, X., He, Q., Tan, L., Wang, R., & Li, F. (2020) · Medicine · doi:10.1097/md.0000000000021869 · Cited by 3
Immunomodulatory effect of stereotactic ablative radiotherapy in lung cancer
Domagala-Kulawik, J. J. (2017) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.4015 · Cited by 2
Pembrolizumab in Small-Cell Lung Cancer: In Search of the Best Biomarker
Smit, E. F., & Haanen, J. B. A. G. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.5141 · Cited by 2
Perspectives on imaging and immunotherapy: a review series
de Vries, E. G. E., & Schwartz, L. H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005006 · Cited by 2
Charlab, R., Leong, R., Shord, S. S., & Reaman, G. H. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041656 · Cited by 2
Rathinagopal, T. J., Bhanot, S. M., Yegrov, S., Min, J., Hu, N., Fang, J. C., Greene, T., Shrivastav, S. V., Singh, H., & Shrivastav, A. (2022) · Annals of Surgery Open · doi:10.1097/as9.0000000000000117 · Cited by 2
Song, P., Wusiman, D., Li, W., Guo, L., Ying, J., Gao, S., & He, J. (2023) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000477 · Cited by 1
What is the relationship between penile cancer and the microbiome? A scoping review
García‐Perdomo, H. A., Granados-Duque, V., & Spiess, P. E. (2024) · Actas Urológicas Españolas (English Edition) · doi:10.1016/j.acuroe.2024.05.001 · Cited by 1
Current insights into the clinico-pathologic characteristics of lung cancer in women
Trojnar, A., & Domagala-Kulawik, J. J. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2475974 · Cited by 1
Liu, Z., Zhao, X., Zang, M., Yuan, H., Qin, X., Li, X., Zhao, S., Tan, R., Yan, K., Liu, L., et al. (2025) · Advanced Science · doi:10.1002/advs.202404200 · Cited by 5
Lee, K. J., Chokshi, S., Joshi, T., Cummings, M., Ramírez‐Alcántara, V., Turbat‐Herrera, E. A., Rocconi, R. P., Scalici, J. M., Pierce, J. Y., & Jones, N. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.07.016 · Cited by 1
Yang, X., Huang, M., Pang, T., Zhong, D., Liu, H., Chen, X., Liu, J., & Wen, Y. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102804 · Cited by 3
Zhang, B., Chen, Z., Mao, R., Zhu, J., Cai, W., & Zhao, B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1771228 · Cited by 1
Horizontal mitochondrial transfer and the tug-of-war between cancer cells and immune cells
Novak, J., Hortova, D., Endaya, B., Krulová, M., Berridge, M. V., & Neužil, J. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.05.008 · Cited by 1
Silibinin is a natural molecular glue that inhibits PD-L1 glycomaturation
Teixidor, E., Encinar, J. A., Martín-Castillo, B., Lupu, R., Bosch‐Barrera, J., Menéndez, J. A., Verdura, S., & Cuyàs, E. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158481 · Cited by 1
Marjanovic, M., Maletin, N., Kukic, B. P., Nikolić, I., Petrović, N., Radić, J., Đurić, A., Knezevic, M., Dejanović, B., & Calic, V. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1907957 · Cited by 1
Highlights of thoracic oncology from the 2018 ERS International Congress
Ntontsi, P., Bostantzoglou, C., & Blum, T. G. (2019) · ERJ Open Research · doi:10.1183/23120541.00222-2018 · Cited by 1
Fuji, S., & Ohmoto, A. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2035716 · Cited by 1
Cancer therapies: Caveats, concerns, and momentum
Anisman, H., & Kusnecov, A. W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91904-3.00001-x · Cited by 1
Adjuvant Immunotherapy as a Tool to Boost Effectiveness of Electrochemotherapy
Kamenšek, U., Kos, Š., & Serša, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-26779-1_105-2 · Cited by 1
Blagosklonny, M. V., & Gudkov, A. V. (2010) · Oncotarget · doi:10.18632/oncotarget.24001 · Cited by 1
Jia, M., Liu, C., Liu, Y., Bao, Z., Jiang, Y., & Sun, X. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm13010013 · Cited by 2
Immune Checkpoint Inhibitors and Anti-Angiogenic Therapy for Cancer
Solimando, A. G., & Ribatti, D. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_163-1 · Cited by 1
Peng, C., Liu, Y., Heng, Y. J., Bodelón, C., Stover, D. G., Chen, W. Y., Holmes, M. D., Eliassen, A. H., Kraft, P. L., & Tamimi, R. M. (2025) · Carcinogenesis · doi:10.1093/carcin/bgaf028 · Cited by 3
Immunotherapy and Lung Cancer: Programmed Death 1 and Its Ligand as a Target for Therapy
Kerr, K. M., & Laing, G. M. (2017) · Molecular pathology library · doi:10.1007/978-3-319-62941-4_20 · Cited by 2
Mudunov, A. M., Ahundov, A. A., Викторович, Б. М., & Брауншвейг, Т. (2018) · Head and neck tumors (HNT) · doi:10.17650/2222-1468-2018-8-1-48-55 · Cited by 1
Machak, G. N. (2018) · Malignant tumours · doi:10.18027/2224-5057-2018-8-2-31-42 · Cited by 1
Predicting Treatment Response Based on RNA Expression in Large Datasets
Mansfield, A. S., & Jen, J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2823 · Cited by 1
Liu, J., Zhang, S., Li, S., & Cheng, Y. (2017) · PubMed Central · doi:10.3779/j.issn.1009-3419.2017.10.06 · Cited by 1
Artificial intelligence and the interplay between tumor and immunity
Saltz, J. H., & Gupta, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-67538-3.00010-5 · Cited by 1
Tissue Infiltrating Immune Cells and Endometrial Cancer Prognosis
Drakes, M. L., Mehrotra, S., Potkul, R. K., Czerlanis, C. M., & Stiff, P. J. (2021) · Clinical Oncology and Research · doi:10.31487/j.cor.2021.04.01 · Cited by 1
Predictive Biomarkers of Melanoma
Hanly, A. M., Gibson, F. T., & Alani, R. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-82639-0_16 · Cited by 1
A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC
Christopoulos, P., & Thomas, M. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.02.86 · Cited by 1
Immune Biomarkers on the Radar—Comprehensive “Immunograms” for Multimodal Treatment Prediction
Botling, J., & Sandelin, M. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.03.009 · Cited by 1
Guiding Cancer Therapy: Evidence-driven Reporting of Genomic Data
Perera‐Bel, J. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7161
Herreros‐Pomares, A. (2020) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/137036 · Cited by 1
Mujeres deshonradas: injuria y traición en la "Medea" de Eurípides
Cidre, E. R. (2000) · Anales de Historia Antigua Medieval y Moderna · doi:10.34096/ahamm.v33.4318 · Cited by 6
PhD, E. V. (2018) · Wiley eBooks · doi:10.1002/9781119126843.ch5 · Cited by 1
Jeong, M.-K., Chun, J., & Oh, I. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154275 · Cited by 1
Adoptive cell therapy and modulation of the tumour microenvironment: new insights from ASCO 2016
Khoja, L., & Gyawali, B. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.ed59
Biomarkers for outcome upon MAPK inhibition in melanoma
Blank, C. U. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30593-9
Patel, S. J. (2017) · DigitalGeorgetown (Georgetown University Library)
Gerritsen, W. R., Westdorp, H., & Haanen, J. B. A. G. (2017) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-0442-4_11
Kranz, L. M., Beck, J. D., Grunwitz, C. R., Hotz, C., Vormehr, M., & Diken, M. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1358327
Primer on Cancer Immunotherapy and the Targeting of Native Proteins
Barsan, V. V., & Tumeh, P. C. (2017) · Current cancer research · doi:10.1007/978-3-319-63757-0_1
Melanoma proteomics unravels major differences related to mutational statusPreprint
Trilla‐Fuertes, L., Gámez‐Pozo, A., Prado-Vázquez, G., Zapater‐Moros, A., Díaz‐Almirón, M., Fortes, C., López‐Vacas, R., Márquez‐Rodas, I., Soria, A., Vara, J. Á. F., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/198358
Predictors of Response to Immune Checkpoint Blockade
Andrews, M. C., & Wargo, J. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_31
Significance of Immune Checkpoints in Lung Cancer
Leventakos, K., & Mansfield, A. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-70622-1_4
Meierjohann, S., & Schilling, B. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00046-6
Schuler, P. J., Witzleben, A. V., Doescher, J., Wollenberg, B., Dietz, A., & Hoffmann, T. K. (2018) · HNO
Personalized Medicine in Oncology Drug Development
Dracopoli, N. C., Grewal, I. S., Takimoto, C. H. M., & Lebowitz, P. F. (2019) · Wiley eBooks · doi:10.1002/9781119000822.hfcm052.pub2
Benchmarking the Foreign Antigen Space of Human MalignanciesPreprint
Slagter, M., Fanchi, L. F., van Buuren, M. M., Velds, A., Calis, J. J. A., Schouten, P. C., Bounova, G., Alexandrov, L. B., Linn, S. C., Veelken, H., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3279415
Noguera, R., Burgos‐Panadero, R., Lucantoni, F., de la Cruz‐Merino, L., & Naranjo, T. Á. (2019) · Revista Española de Patología · doi:10.1016/j.patol.2019.08.001 · Cited by 1
Immunotherapy-Based Approaches for Treatment of Oral and Oropharyngeal Cancers
Wollenberg, B. (2020) · Textbooks in contemporary dentistry · doi:10.1007/978-3-030-32316-5_28
Wind, A., van Harten, W. H., Smeland, S., Pieve, L. D., & Groen, W. G. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108855440.005
Pharmacokinetics, Pharmacodynamics, and Toxicology Aspects of Immunotherapeutics
Kulkarni, P. D., Mehta, P., Shriyan, B., Gawit, K., Gota, V., & Ghante, M. R. (2020) · Springer eBooks · doi:10.1007/978-981-15-9038-2_9
Novel biomarkers for melanoma immunotherapy
Wong, N. M. A. (2020) · Minerva Access (University of Melbourne)
Urrego-Callejas, T., Soto-Restrepo, J. F., Sandoval-Álvarez, S., Chvatal‐Medina, M., Gómez, R., & Vásquez, G. M. (2021) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2020.11.001
Leveraging technological opportunities in cancer genomics
Valle-Inclán, J. E. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/480
Microphaser - a small-scale phasing approach for improved personalized neopeptidome creationPreprint
Förster, J., Laehnemann, D., Paschen, A., Schramm, A. R., Schüler, M., & Köster, J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.11.455827
Malignes Melanom: Resistenzen unter PD-1-Blockade
Berger, D. (2021) · Der Deutsche Dermatologe · doi:10.1007/s15011-021-4726-8
Therapeutic Intervention in Skin Cancer: Future Prospects
Srivastava, R. (2021) · Springer eBooks · doi:10.1007/978-981-16-0364-8_2
Vaccine-Enhanced Adoptive T-Cell Therapy to Treat Canine Cancers
Reyes, N., & Wood, G. W. (2021) · Advances in Small Animal Care · doi:10.1016/j.yasa.2021.07.007
Autoantibodies: A manifestation of immune related adverse events of cancer immunotherapy
Urrego-Callejas, T., Soto-Restrepo, J. F., Sandoval-Álvarez, S., Chvatal‐Medina, M., Gómez, R., & Vásquez, G. M. (2021) · Revista Colombiana de Reumatología (English Edition) · doi:10.1016/j.rcreue.2020.11.002
Improving immunotherapy responses in gastrointestinal cancers
Chalabi, M. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/904
(2021) · Elsevier eBooks · doi:10.1016/b978-3-437-21432-5.00020-0
(2017) · Elsevier eBooks · doi:10.1016/b978-3-437-21431-8.16001-6
Kijima, T., Kubo, T., Nishihara, D., Nukui, A., Hirohashi, Y., Torigoe, T., & Kamai, T. (2022) · Research Square · doi:10.21203/rs.3.rs-1344442/v1
Fukui, T., Hosotani, S., Soda, I., Ozawa, T., Kusuhara, S., Kakegawa, M., Kasajima, M., Hiyoshi, Y., Igawa, S., Yokoba, M., et al. (2019) · doi:10.21203/rs.2.16193/v1
Adjuvant Immunotherapy as a Tool to Boost Effectiveness of Electrochemotherapy
Kamenšek, U., Kos, Š., & Serša, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-26779-1_105-1
Eisenlohr, L. C., & Cosma, G. L. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726981821.793545053
Marabelle, A., & Gray, J. C. (2017) · Springer eBooks · doi:10.1007/978-3-319-43486-5_13
Gerritsen, W. R., Westdorp, H., & Haanen, J. B. A. G. (2020) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2449-1_11
T-Cell Based Therapies: Clinical Applications and Challenges
Figueroa, I., Gupta, A., & Peighambari, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_185-1
Strahlentherapie und Immuntherapie
Gaipl, U. S., Grosu, A., Frey, B., Rückert, M., Schäfer, H. S., & Popp, I. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_177-1
Optimising Cancer Immunotherapy: Challenges and Opportunities
Stoddert, T. G. (2016) · European Medical Journal · doi:10.33590/emj/10314662
Mouritzen, M. T. (2022) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau515553116
An Immune-Related Gene Signature for Determining Tumor Prognosis Based on Machine Learning
Yazdanpanah, F., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_310-1
Phytochemicals in prostate cancer
Tawaha, A. R. A., Abukhader, R., Qaisi, A. M., Dey, A., Pati, S., Al‐Tawaha, A. R., Ali, I., & SHATNAWI, M. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19143-5.00022-0
Azees, S. A., Manoharan, R., Navaneeth, A. G., Leon, B. S., & Karthikeyan, S. (2023) · Research Square · doi:10.21203/rs.3.rs-3241930/v1
Gorris, M. A. J., Martynova, E., Sweep, M. W. D., van der Hoorn, I. A. E., Sultan, S., Claassens, M. J. D. E., van der Woude, L. L., Verrijp, K., Figdor, C. G., Textor, J. C., et al. (2023) · doi:10.3791/65717-v
Benzekry, S., Karlsen, M., Bigarré, C., Kaoutari, A. E., Gomes, B., Stern, M., Neubert, A., Bruno, R., Mercier, F., Vatakuti, S., et al. (2023) · medRxiv · doi:10.1101/2023.09.26.23296135
Metadata
- Authors
- Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N.
- Affiliations
- The Netherlands Cancer Institute (NL)
- University of California, Los Angeles (US)
- Venue
- Science
- Published
- 2016-05-06
- Volume
- 352
- Issue
- 6286
- Pages
- 658-660
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2346108121
- Cited by
- 748
- References
- 36
- Citations by year
- 2026: 23 · 2025: 37 · 2024: 54 · 2023: 61 · 2022: 66 · 2021: 92 · 2020: 113 · 2019: 78 · 2018: 104 · 2017: 94 · 2016: 23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor-immune interactions, tumor immune microenvironment, immune checkpoint inhibitors, precision oncology, immune profiling
- MeSH terms
- Animals, Humans, Immunotherapy, Macrophages, Neoplasms, T-Lymphocytes, Biomarkers, Tumor, Lymphocytes, Tumor-Infiltrating, Tumor Escape, Mice, Precision Medicine, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.